Hormone Sensitive Prostate Cancer Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled332 locationsNCT07028853
Recruiting
Phase 1
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.12 enrolled1 locationNCT07339267